Bli medlem
Bli medlem

Du är här


Immunicum AB: Immunicum submits IND application to the Food and Drug Administration (FDA) for approval to treat kidney cancer patients in the United States in i

Gothenburg, Sweden, July 22, 2016 - Immunicum AB (publ), a biopharmaceutical
company pursuing to develop sophisticated, safe and efficient therapeutic
cancer treatments with powerful and long lasting immune responses, today
announced that the Company has submitted an Investigational New Drug (IND)
application to the Food and Drug Administration (FDA) in the U.S. The
application is requesting approval to treat kidney cancer patients in the
U.S. with Immunicum's lead cancer immune primer, INTUVAX®, in its ongoing
MERECA (MEtastatic REnal cell CArcinoma) phase II-trial.

Immunicum's INTUVAX® is a unique cancer immune primer currently being tested
in clinical trials for the treatment of kidney cancer and liver cancer as
well as GIST (gastrointestinal stromal tumor). As previously reported,
results from Immunicum's completed phase I/II-trial for treatment of kidney
cancer have been promising.

Today's announcement of the submission of the IND application to the FDA is
one more step forward in the Company's clinical plans to expand it's testing
of INTUVAX® into the U.S. Approval from the FDA is expected within 30 days.

For further information, please contact:

Jamal El-Mosleh, CEO, Immunicum

Phone: +46 (0) 31 41 50

The Company's Certified Adviser is Redeye AB Phone: +46 (0) 8 545 013


INTUVAX is a cancer immune primer, developed for the treatment of solid
tumors. Its active ingredient is activated white blood cells, so called
dendritic cells, derived from healthy blood donors. Intratumoral injection of
these cells is expected to lead to an inflammatory response which in turn
leads to tumor-specific activation of the patient's cytotoxic T lymphocytes.

About Immunicum AB (publ)

Immunicum AB (publ) is working to develop and advance cancer immune primers
for the treatment of tumor diseases. A clinical phase II trial for the
Company's most advanced product - INTUVAX® against kidney cancer - has been
initiated. The project portfolio contains additional clinical phase I/II
studies in liver cancer and in gastrointestinal stromal tumors (GIST).

For more information, please


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.